ClinVar Miner

Submissions for variant NM_000527.5(LDLR):c.259T>G (p.Trp87Gly) (rs121908025)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 20
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000844748 SCV000271387 pathogenic Homozygous familial hypercholesterolemia 2015-12-21 criteria provided, single submitter clinical testing The p.Trp87Gly variant in LDLR is a well-established pathogenic variant for fami lial hypercholesterolemia (Leitersdorf 1990, Jensen 1996, Vohl 1997, Tybjaerg-Ha nsen 2005, Futema 2013), and is a known founder mutation in the French Canadian population where it has been reported in >400 individuals with FH, including >15 homozygous individuals (Vohl 1997). It has also been identified in 7/126722Euro pean chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broad institute.org; dbSNP rs121908025); however, this frequency is low enough to be c onsistent with the frequency of FH in the general population. Additionally, in v itro functional studies provide some evidence that the p.Trp87Gly variant may im pact protein function (Leitersdorf 1990). In summary, this variant meets our cri teria to be classified as pathogenic for FH in an autosomal dominant manner base d upon its identification in a large number of affected individuals and low freq uency in controls. ACMG/AMP Criteria applied: PS4; PM3; PM2_Supporting; PP3; PS3 _Supporting.
Invitae RCV000776466 SCV000285027 pathogenic Familial hypercholesterolemia 2020-10-20 criteria provided, single submitter clinical testing This sequence change replaces tryptophan with glycine at codon 87 of the LDLR protein (p.Trp87Gly). The tryptophan residue is highly conserved and there is a large physicochemical difference between tryptophan and glycine. This variant is clearly defined as a familial hypercholesterolemia causative allele (PMID: 2318961, 12553167, 16542394). It is a founder mutation in the Dutch population, and is common in individuals of European ancestry. This variant is also known as p.W66G in the literature. ClinVar contains an entry for this variant (Variation ID: 3685). Experimental studies have shown that this missense change leads to an LDL receptor protein that is unable to properly bind LDL (PMID: 8098448). For these reasons, this variant has been classified as Pathogenic.
LDLR-LOVD, British Heart Foundation RCV000003870 SCV000294560 likely pathogenic Familial hypercholesterolemia 1 2016-03-25 criteria provided, single submitter literature only
Robarts Research Institute,Western University RCV000003870 SCV000484716 likely pathogenic Familial hypercholesterolemia 1 criteria provided, single submitter clinical testing
Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies,APHP, GH Hôpitaux Universitaires Pitié-Salpêtrière / Charles-Foix RCV000003870 SCV000503120 likely pathogenic Familial hypercholesterolemia 1 2016-12-16 criteria provided, single submitter clinical testing subjects mutated among 2600 FH index cases screened = 9 , family members = 7 with co-segregation / frequently associated with c.1975A>C, p.Thr659Pro (2 index cases), Subnormal LDLR activity / Software predictions: Damaging
Molecular Genetics Laboratory,Centre for Cardiovascular Surgery and Transplantation RCV000003870 SCV000540721 likely pathogenic Familial hypercholesterolemia 1 2016-11-05 criteria provided, single submitter clinical testing
U4M - Lille University & CHRU Lille, Université de Lille - CHRU de Lille RCV000003870 SCV000583644 pathogenic Familial hypercholesterolemia 1 2017-03-30 criteria provided, single submitter clinical testing
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease,Montreal Heart Institute RCV000622852 SCV000740415 likely pathogenic not provided 2017-07-11 criteria provided, single submitter clinical testing
Color Health, Inc RCV000776466 SCV000912015 pathogenic Familial hypercholesterolemia 2018-01-29 criteria provided, single submitter clinical testing Pathogenic variant based on current evidence: This missense variant (also known as p.Trp66Gly in the mature protein) is located in the second LDLR type A repeat of the ligand binding domain of the LDLR protein. Computational prediction tools and conservation analyses suggest that this variant may have deleterious impact on the protein function. Computational splicing tools suggest that this variant may not impact the RNA splicing. Experimental studies have demonstrated that the variant protein showed reduced LDL binding (PMID: 8645371, 10735631). This variant has been identified in over 500 individuals affected with familial hypercholesterolemia (PMID: 8098448, 9272705, 12553167, 16542394, 2318961). This variant is common in individuals of European descent and is considered a founder mutation in the French-Canadian population (PMID: 9272705). Homozygous individuals have shown much higher LDL-C levels than heterozygous individuals (PMID: 8098448). This variant has been identified in 8/277232 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on available evidence, this variant is classified as Pathogenic.
Institute of Human Genetics, University of Leipzig Medical Center RCV000003870 SCV001428736 likely pathogenic Familial hypercholesterolemia 1 2020-02-03 criteria provided, single submitter clinical testing
Brunham Lab, Centre for Heart and Lung Innovation,University of British Columbia RCV000003870 SCV001432641 pathogenic Familial hypercholesterolemia 1 2019-03-13 criteria provided, single submitter research
Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine RCV000776466 SCV001435004 pathogenic Familial hypercholesterolemia 2020-02-04 criteria provided, single submitter clinical testing The c.259T>G (p.Trp87Gly) variant in the LDLR gene has been reported in multiple individuals with familial hypercholesterolemia (PMID: 2318961, 8054972, 8645371, 9259195, 9104431). It is located in the functionally important second LDLR type A repeat. Functional studies have demonstrated a deleterious effect of the p.Trp87Gly variant on LDL binding (PMID: 2318961, 8645371, 10735631). The variant is observed in gnomAD at a low minor allele frequency (8/282882). Multiple algorithms predicted this change to be deleterious. Therefore, the c.259T>G (p.Trp87Gly) variant in the LDLR gene is classified as pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000776466 SCV001467951 pathogenic Familial hypercholesterolemia 2020-12-14 criteria provided, single submitter clinical testing Variant summary: LDLR c.259T>G (p.Trp87Gly) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 251490 control chromosomes. c.259T>G has been reported in the literature in multiple individuals affected with Familial Hypercholesterolemia (e.g. Leitersdorf_1990, Moorjani_1993, Banerjee_2019). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function, indicating the cells expressing the variant have reduced LDL-binding and uptake (e.g. Banerjee_2019). 11 clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories cited the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Johns Hopkins Genomics, Johns Hopkins University RCV000003870 SCV001711949 pathogenic Familial hypercholesterolemia 1 2021-05-28 criteria provided, single submitter clinical testing This variant (rs121908025) is rare (<0.1%) in a large population database (gnomAD: 8/282882 total alleles, 0.003%, no homozygotes) and has an entry in ClinVar. It has been reported in multiple individuals with familial hypercholesterolemia-1, and is considered a founder mutation in the French-Canadian population. This variant is located in the second type A repeat of the ligand binding domain of the LDLR protein. Functional studies have demonstrated a deleterious effect of p.Trp87Gly on LDL binding and uptake. This variant was also identified in the patient's father, who has a personal history of elevated cholesterol. We consider c.259T>G to be pathogenic.
Mayo Clinic Laboratories, Mayo Clinic RCV000622852 SCV001715234 pathogenic not provided 2021-02-10 criteria provided, single submitter clinical testing PS4, PS3_supporting, PM3, PM2_supporting, PP3, PP4
Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine RCV000003870 SCV001754778 pathogenic Familial hypercholesterolemia 1 2020-02-04 criteria provided, single submitter clinical testing The c.259T>G (p.Trp87Gly) variant in the LDLR gene has been reported in multiple individuals with familial hypercholesterolemia (PMID: 2318961, 8054972, 8645371, 9259195, 9104431). It is located in the functionally important second LDLR type A repeat. Functional studies have demonstrated a deleterious effect of the p.Trp87Gly variant on LDL binding (PMID: 2318961, 8645371, 10735631). The variant is observed in gnomAD at a low minor allele frequency (8/282882). Multiple algorithms predicted this change to be deleterious. Therefore, the c.259T>G (p.Trp87Gly) variant in the LDLR gene is classified as pathogenic.
GeneDx RCV000622852 SCV001818531 pathogenic not provided 2020-11-17 criteria provided, single submitter clinical testing Reported as likely pathogenic/pathogenic in ClinVar but additional evidence is not available (ClinVar Variant ID# 3685; Landrum et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; LDL receptor activity was significantly reduced in the fibroblasts from two of three unrelated individuals who were homozygous for the FH French Canadian-4 allele (Hobbs et al., 1992) and this variant affects either LDLR turnover or the binding of the LDLR protein to LDL (Leitersdorf et al., 1990); This variant is associated with the following publications: (PMID: 32770674, 32719484, 33303402, 32041611, 31727422, 29407885, 31401775, 29874871, 29261184, 30512145, 30586733, 1301956, 2318961, 9272705, 12381843, 9767373, 28008010, 24281370, 23669246, 15528480, 16542394, 8645371, 9259195, 9104431)
OMIM RCV000003870 SCV000024035 pathogenic Familial hypercholesterolemia 1 1994-04-01 no assertion criteria provided literature only
Cardiovascular Genetics Laboratory,PathWest Laboratory Medicine WA - Fiona Stanley Hospital RCV000003870 SCV000268547 pathogenic Familial hypercholesterolemia 1 2008-12-18 no assertion criteria provided clinical testing
Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde,Academisch Medisch Centrum RCV000003870 SCV000606051 pathogenic Familial hypercholesterolemia 1 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.